OC-0130: Dose effect relationships for rectal bleeding after MRI-guided adaptive brachytherapy for cervical cancer  by Mazeron, R. et al.
3rd ESTRO Forum 2015                                                                                                                                         S61 
 
the D90 of the HR-CTV and 75 Gy to 90% of the IR-CTV (in 2 
Gy equivalent, α/β=10). To warrant the same local control 
rate, the D90 HR-CTV should be significantly increased in 
stage III-IV tumors, in case of HR-CTV > 30 cm3, excessive 
treatment time, or tumor width at diagnosis > 5 cm (97, 92, 
105, and 92 Gy respectively). Combining the two indepedent 
local prognosis factors: OTT < 56 days and HR-CTV volume < 
30 cm3; OTT > 55 days and HR-CTV volume < 30 cm3, OTT < 
56 days and HR-CTV volume ≥ 30 cm3, and OTT > 55 days and 
HR-CTV volume > 30 cm3, expected local control rates were 
94.3%, 86.6%, 81.7%, and 64.5% respectively, for a planned 
D90 of 85 Gy (p=0.001). 
Conclusions: Overall treatment time and HR-CTV volume 
were independent prognostic factors for local control. The 
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Purpose/Objective: To establish dose volume-effect 
relationships for late rectal bleeding in cervix cancer patients 
treated with chemoradiation and MRI-guided adaptive 
brachytherapy within a prospective longitudinal multicenter 
study (EMBRACE study Aim 6). 
Materials and Methods: The first 700 patients included in the 
EMBRACE study were selected. Patients were included prior 
to treatment initiation, and treated with curative intent 
according to institutional protocols. Reporting followed the 
GEC-ESTRO recommendations (D0.1cm3, D2 cm3 OAR). During 
follow-up assessments of morbidity (CTC-AE 3.0) including 
rectal bleeding was conducted 3, 6, 9, 12, 18, 24, 30, 36, 48, 
and 60 months after treatment completion. Late morbidity 
was defined as any event occurring or lasting over 90 days 
after treatment initiation. Patients with missing D2cm3, or 
follow-up less than 90 days from treatment initiation were 
excluded. All doses were converted in 2 Gy equivalent using 
the linear quadratic model and α/β=3 Gy. In case of multiple 
events in a single patient, the one with the highest grade was 
retained for analysis. Dose effect-relationships were assessed 
using log rank tests and the probit model. 
Results: A number of 634 patients fulfilled the inclusion 
criteria. Mean age was 50.6 years (22.2-91.6), and 94.6% of 
the patients received concomitant chemotherapy. The 
median follow-up was 31.5 months (3-66). The mean DICRU, 
D0.1cm3, and D2cm3 were 66.3+/-8.3 Gy, 73.4+/-11.8 Gy, 
and 63.2+/-7.2 Gy, respectively. A total of 223 events was 
reported, 0.35 per patient (0-6). 117 patients had rectal 
bleeding: 87 grade 1 (13.7%), 22 grade 2 (3.5%), and 8 grade 
3 (1.3%). No grade 4 was reported. The mean time to onset 
was 18.0+/-9.5 months. Monitoring of the prevalence of 
grade 1-4 events showed an increasing rate of rectal bleeding 
from 3 months to 2 years (2.5 and 11.6% respectively) 
followed by a trend to recovery (8.1% and 5.6% at 30 and 36 
months). Actuarial cumulative incidences of grade 1-4, 2-4, 
and 3-4 were 24%, 6.8%, and 2% respectively at 3 years. 
Sorting patients according to dose levels (D2cm3 >75 Gy, 70-
75, 65-70, 60-65, 55-60, and 3, for grade 1-4, and 2-4 events 
(p3 and D0.1cm3 and the probability of grade 1-4, 2-4, and 3-
4 events, as well as between DICRU and grade 1-4, 2-4, but 
not for grade 3-4 events. According to this model, a dose 
constraint of 75 Gy for the D2cm3 corresponded to 31%, 9.7%, 
and 3%, of grade 1-4, 2-4, and 3-4 rectal bleeding 
respectively. Decreasing this constraint to 70 Gy would lead 
to probabilities of 25%, 7%, and 2% respectively. 
Conclusions: Significant dose volume-effect correlations 
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Purpose/Objective: To report the dosimetric parameters and 
clinical outcome of locally advanced cervical cancer (LACC) 
patients treated with radiochemotherapy (RCT) and MR-
guided pulsed-dose-rate (PDR) adaptive brachytherapy 
(IGABT). 
Materials and Methods: Between 2007 and 2013 one hundred 
thirty-three patients with FIGO stage 1B1 N+ or ≥ 1B2 cervical 
cancer were treated with RCT+IGABT. Treatment schedule 
included a pelvic±paraaortic external beam radiotherapy 
